Stocks Health care PPBT
NASDAQ · Health carePurple Biotech Ltd. (PPBT)
It posted a net loss of $26.4M. In fiscal 2025 capital spending exceeded operating cash flow by $5.7M. At December 31, 2025 it held $8.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 19, 2026.
Key facts about Purple Biotech Ltd.
- Net worth
- Purple Biotech Ltd. has a market value (market cap) of $2.4M at the latest share price, and shareholders' equity of $9.7M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $5.7M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 19, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Purple Biotech Ltd. does
Purple Biotech Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPBT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.4M | $0.03 | -$5.7M |
| 2024 | n/a | -$7.2M | $4.99 | n/a |
| 2023 | n/a | -$19.9M | $17.96 | -$19.9M |
| 2022 | n/a | -$21.7M | $23.97 | -$16.8M |
| 2021 | n/a | $17.8M | $23.29 | -$489K |
| 2020 | $1M | $28.7M | $0.00 | $1.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Purple Biotech Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026
- September 9, 2026
- September 2, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 7, 2026
- July 29, 2026
- June 23, 2026
- June 11, 2026
- May 20, 2026Form F-3 filing F-3
Insider trades
What the people running Purple Biotech Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns PPBT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mitchell P. Kopin13G, passive with 2 related filers | 9.99% | May 13, 2026 |
| Lincoln Alternative Strategies LLC13G, passive | 9.9% | September 9, 2025 |
| Armistice Capital, LLC13G, passive with 1 related filers | 8.69% | November 14, 2024 |
Largest institutional holders
Insiders
Questions about PPBT
What does Purple Biotech Ltd. do?
Purple Biotech Ltd. is a company in the Health care sector, listed on NASDAQ as PPBT. Its shares trade on NASDAQ under the ticker PPBT.
What is Purple Biotech Ltd.'s net worth?
Purple Biotech Ltd. has a market value (market cap) of $2.4M at the latest share price, and shareholders' equity of $9.7M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Purple Biotech Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $26.4M.
When did Purple Biotech Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 19, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 5, 2026.
Similar companies
Compare PPBT with
Follow PPBT
Get an email when Purple Biotech Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Purple Biotech Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.